Powered by cutting-edge genetics
We are developing transformative, clinically validated oral therapies for patients with metabolic diseases.
Our Mission
At NewAmsterdam Pharma, we are passionate about providing transformational therapies for patients suffering from an array of conditions where aberrant cholesterol metabolism still underlies significant morbidity and mortality despite treatment with existing standards of care. We are developing safe, convenient, oral medications for metabolic diseases to help transform the treatment paradigm for these patients.
Our Science
Our lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been shown in clinical trials to significantly reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). CETP functions to transport cholesterol from good HDL to bad LDL. Obicetrapib works by blocking this transfer, thus substantially lowering LDL while simultaneously increasing HDL. We believe by transforming the ratio of good versus bad cholesterol in the body, obicetrapib holds transformative treatment potential for patients.
ROBUST GENETIC MECHANISM. Blocking CETP exhibits a strong genetic linkage to human metabolic diseases. CETP loss of function is considered a longevity gene, and people with CETP loss of function have been observed to be significantly less likely to develop metabolic diseases, such as coronary artery disease, diabetes, and Alzheimer’s disease. Similarly, gain-of-function mutations in CETP are associated with significant increases in the risk for these diseases.
CLINICAL RESULTS. CETP inhibition has also been observed in clinical trials to decrease the risk of adverse cardiovascular outcomes. In the REVEAL trial of 30,000 hyperlipidemia patients, anacetrapib demonstrated LDL-lowering with a CETP inhibitor reduced cardiovascular outcomes in patients by 9% after 4.1 years and 20% after 6.4 years, a degree consistent with expectations based on magnitude of LDL decrease. Additionally, 4 prior CETP inhibitors have all shown clinical benefit in diabetes in clinical trials of over 90,000 patients. Obicetrapib is differentiated from these prior compounds due to an improved selectivity and potency for CETP, as well as the safety and tolerability profile observed to date.
Obicetrapib has the potential to be a safe, convenient, low-dose, once-daily oral therapy that can meaningfully improve the landscape of metabolic diseases.